Johnson Matthey launches joint effort
Johnson Matthey Pharmaceutical Materials Division launched a worldwide joint marketing effort among its business units, coinciding with new market identities for three of them.
Johnson Matthey Pharmaceutical Materials Division launched a worldwide joint marketing effort among its business units, coinciding with new market identities for three of them.
The new effort will focus on the provision of cGMP API development and manufacturing solutions, spanning the entire drug development pipeline and including specialised expertise in controlled drug handling and manufacturing.
The launch of the new market identities coincides with the effort to further enhance the cohesive network formed by the combined units within the Pharmaceutical Materials Division:
• Johnson Matthey Pharma Services (formerly Pharm-Eco), of Devens, MA, a leader in contract API manufacture (up to 500 gallons) and complex contract chemistry services as well as separation technologies;
• Johnson Matthey Pharmaceutical Materials USA, of West Deptford, NJ, which produces bulk APIs up to 2000 gallons, specialising in controlled substances;
• Johnson Matthey Pharmaceutical Materials Ireland (formerly Cascade Biochem Ltd.) based in Cork, Ireland, a leader in prostaglandin development and manufacture;
• Johnson Matthey Macfarlan Smith, Edinburgh, Scotland, leader in controlled drug development and manufacture as well as natural product extraction.